Citation Impact
Citing Papers
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
2013
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
2014
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
The Cardiovascular Biology of Glucagon-like Peptide-1
2016
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
2016
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Type 2 diabetes
2017 Standout
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
2014
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
2020
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
2014
The Discovery and Development of Liraglutide and Semaglutide
2019
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Immunogenicity of long-lasting recombinant factor VIII products
2015
Type 2 diabetes mellitus
2015 Standout
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
2017
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
2021
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials
2015
Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis
2016
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
2015
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials
2016
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
2016
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Targeting orphan G protein‐coupled receptors for the treatment of diabetes and its complications: C‐peptide andGPR 146
2016
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
2016
Novel Agents for the Treatment of Type 2 Diabetes
2014
The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies
2021 Standout
Diabetic Kidney Disease
2017 Standout
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
2021
GLP-1 receptor agonists: a review of head-to-head clinical studies
2014
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
2016
Developing a New Definition and Assessing New Clinical Criteria for Septic Shock
2016 Standout
Sepsis-Induced Immunosuppression
2021
Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis
2016
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
2015
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of June Ye being referenced
Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements
2015
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
2014
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
2019
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
2014
A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus
2014
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*
2019
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
2015
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
2012